false
0001472012
0001472012
2023-11-09
2023-11-09
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C.
20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
November 9, 2023
Immunome,
Inc.
(Exact name of registrant as specified in its
charter)
Delaware |
|
001-39580 |
|
77-0694340 |
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification
No.) |
665
Stockton Drive, Suite 300
Exton, Pennsylvania |
|
19342 |
(Address of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (610)
321-3700
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b)
of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
Stock, $0.0001 par value per share |
|
IMNM |
|
The Nasdaq
Capital Market |
Indicate by check mark
whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter)
or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth
company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02 Results
of Operations and Financial Condition.
On
November 9, 2023, Immunome, Inc. announced its financial results for the third quarter ended September 30, 2023 in
the press release attached here to as Exhibit 99.1 and incorporated herein by reference.
The
information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Section 11
and 12(a)(2) of the Securities Act of 1933, as amended. The information shall not be deemed incorporated by reference into any other
filing with the Securities and Exchange Commission made by the Company, whether made before or after today’s date, regardless of
any general incorporation language in such filing, except as shall be expressly set forth by specific references in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
IMMUNOME, INC. |
|
|
|
Date: November 9,
2023 |
By: |
/s/ Corleen Roche |
|
|
Corleen Roche |
|
|
Chief Financial Officer |
Exhibit 99.1
Immunome Reports Third Quarter 2023 Financial Results
- Completed
merger with Morphimmune and concurrent $125 million private placement investment with leading institutional investors -
-
Clay B. Siegall, Ph.D., former co-founder & CEO of Seagen, Inc., appointed as Chairman and CEO -
-
Bob Lechleider, M.D., appointed as Chief Medical Officer –
-
Jean-Jacques Bienaimé, former CEO of BioMarin appointed as member of the Board of Directors -
- Cash
runway expected to extend into Q1 2026* -
SEATTLE,
WA & EXTON, PA – November 9, 2023 – Immunome, Inc. (Nasdaq: IMNM), a biotechnology company dedicated
to developing first-in-class and best-in-class targeted cancer therapies, today reported financial results for the third quarter ended
September 30, 2023 and provided a corporate update.
“The merger of Immunome and Morphimmune is a transformative transaction
for both companies, resulting in a combined company with a highly focused technology platform based upon strong foundational science,
coupled with a strong balance sheet, as we push forward in our mission to develop targeted cancer therapies for patients,” stated
Clay B. Siegall, Ph.D., Chairman and Chief Executive Officer of Immunome. “There remains a significant need for innovative and best
in class treatments to address unmet medical needs for cancer patients where previous approaches have fallen short.”
Highlights
| · | Immunome and Morphimmune Complete Merger with $125 Million
PIPE to Accelerate Development of Novel Targeted Cancer Therapies. In October 2023, Immunome
and Morphimmune, a private biotechnology company
focused on developing targeted oncology therapeutics, announced that the two companies successfully
closed their previously announced merger agreement. |
| o | The newly combined company features synergistic platforms that we believe will enable the development of first-in-class and best-in-class
targeted cancer therapies across multiple modalities and tumor types. |
| o | The concurrent oversubscribed private placement investment of $125 million included participation from Enavate Sciences, EcoR1 Capital,
Redmile Group, Janus Henderson Investors, Avidity Partners, Woodline Partners LP, and other leading institutional investors. |
| · | IMM-ONC-01: We expect to provide guidance in Q1 2024 regarding our timeline to submit to the FDA an IND for IMM-ONC-01. |
| · | 177Lu-FAP: We anticipate an IND submission with the FDA in Q1 2025. |
Financial Highlights
| · | Collaboration Revenue: Collaboration Revenue from the Collaboration Agreement with AbbVie for the three months ended September 30,
2023 was $4 million. |
| · | Research and development (R&D) expenses: R&D expenses for the three months ended September 30, 2023 were
$4 million. |
| · | General and administrative (G&A) expenses: G&A expenses for the three months ended September 30, 2023 were
$4 million. |
| · | Net loss: Net loss for the three months ended September 30, 2023 was $4 million, or $(0.36) per share. |
| · | Cash and cash equivalents: As of September 30, 2023, cash and cash equivalents totaled $91million** |
About Immunome, Inc.
Immunome is a biotechnology company dedicated to developing first-in-class
and best-in-class targeted cancer therapies. Our portfolio pursues each target with a modality appropriate to its biology, including immunotherapies,
targeted effectors, radioligand therapies and ADCs. We believe that pursuing underexplored targets with appropriate drug modalities leads
to transformative therapies. Our proprietary memory B cell hybridoma technology allows for the rapid screening and functional characterization
of novel antibodies and targets.
For more information, visit www.immunome.com or follow us on
Twitter and LinkedIn.
*Assumes receipt of certain collaboration payments.
**Includes $61 million of PIPE proceeds received in the quarter.
Cautionary Statement Regarding
Forward-Looking Statements
Certain statements contained
in this communication regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E
of the Securities and Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995 (the “PSLRA”).
We use words such as “believes,” “plans,” “expects,” “will,” “assumes,” “anticipates,”
and similar expressions to identify these forward-looking statements that are intended to be covered by the safe-harbor provisions of
the PSLRA. These forward looking statements include, but are not limited to, statements regarding Immunome’s anticipated cash runway
and the assumed receipt of certain collaboration payments; Immunome’s intent to evaluate synergistic high-value oncology assets;
Immunome’s timing and expectation for nominating a potential development candidate and filing NDAs with the FDA; Immunome’s
expectation that the combination with Morphimmune will enable to development of first-in-class and best-in-class targeted cancer therapies
across multiple modalities and tumor types; and other statements regarding management’s intentions, plans, beliefs, expectations
or forecasts for the future. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected.
Such forward-looking statements are based on our expectations and involve risks and uncertainties; consequently, actual results may differ
materially from those expressed or implied in the statements due to a number of factors, including, but not limited to, the inability
to recognize the anticipated benefits of the merger, which may be affected by, among other things, competition and the ability of Immunome
to successfully integrate with Morphimmune; Immunome’s ability to grow and successfully execute on its business plan, including
advancing its current pipeline into the clinic and expanding its pipeline through its technology platforms, proprietary toolbox, and through
strategic transactions, if any; the ability of Immunome to identify, conduct and complete IND-enabling studies; changes in the applicable
laws or regulations; the possibility that Immunome may be adversely affected by other economic, business, and/or competitive factors;
the risk that regulatory approvals for Immunome’s programs and product candidates are not obtained, are delayed or are subject to
unanticipated conditions that could adversely affect it or the expected benefits of the merger; Immunome’s ability to manage clinical
trials or studies; the risk that pre-clinical data may not be predictive of clinical data; the complexity of numerous regulatory and legal
requirements that Immunome needs to comply with to operate its business; the reliance on Immunome’s management; the prior experience
and successes of the Immunome’s management team are not indicative of any future success; uncertainties related to Immunome’s
capital requirements and Immunome’s expected cash runway; the failure to obtain, adequately protect, maintain or enforce Immunome’s
intellectual property rights; and other risks and uncertainties indicated from time to time described in Immunome’s Annual Report
on Form 10-K for the year ended December 31, 2022 filed with Securities and Exchange Commission (“SEC”) on March 16,
2023, Immunome’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 filed with the SEC today,
, and in Immunome’s other filings with the SEC. Immunome cautions that the foregoing list of factors is not exclusive and not to
place undue reliance upon any forward-looking statements which speak only as of the date made. Moreover, Immunome operates in a very
competitive and rapidly changing environment. New risks emerge from time to time. Except as required by law, Immunome does not undertake
any obligation to update publicly any forward-looking statements for any reason after the date of this press release to conform these
statements to actual results or to changes in their expectations.
IMMUNOME, INC.
Condensed Balance Sheets
(In thousands, except share data)
(unaudited)
| |
September 30, 2023 | | |
December 31, 2022 | |
Assets | |
| | | |
| | |
Current assets: | |
| | | |
| | |
Cash and cash equivalents | |
$ | 90,641 | | |
$ | 20,323 | |
Prepaid expenses and other current assets | |
| 773 | | |
| 2,326 | |
Total current assets | |
| 91,414 | | |
| 22,649 | |
Property and equipment, net | |
| 1,172 | | |
| 681 | |
Operating right-of-use asset, net | |
| 345 | | |
| 284 | |
Restricted cash | |
| 100 | | |
| 100 | |
Deferred offering costs | |
| 130 | | |
| 332 | |
Total assets | |
$ | 93,161 | | |
$ | 24,046 | |
Liabilities and stockholders’ equity | |
| | | |
| | |
Current liabilities: | |
| | | |
| | |
Accounts payable | |
$ | 2,786 | | |
$ | 2,400 | |
Accrued expenses and other current liabilities | |
| 3,369 | | |
| 4,931 | |
Deferred revenue, current | |
| 16,956 | | |
| — | |
Total current liabilities | |
| 23,111 | | |
| 7,331 | |
Deferred revenue, non-current | |
| 2,852 | | |
| — | |
Deposit liability | |
| 61,000 | | |
| — | |
Other long-term liabilities | |
| 122 | | |
| 62 | |
Total liabilities | |
| 87,085 | | |
| 7,393 | |
Commitments and contingencies (Note 7) | |
| | | |
| | |
Stockholders’ equity: | |
| | | |
| | |
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued or outstanding at September 30, 2023 and December 31, 2022, respectively | |
| — | | |
| — | |
Common stock, $0.0001 par value; 200,000,000 shares authorized; 12,202,516 and 12,128,843 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively | |
| 1 | | |
| 1 | |
Additional paid-in capital | |
| 136,248 | | |
| 132,653 | |
Accumulated deficit | |
| (130,173 | ) | |
| (116,001 | ) |
Total stockholders’ equity | |
| 6,076 | | |
| 16,653 | |
Total liabilities and stockholders’ equity | |
$ | 93,161 | | |
$ | 24,046 | |
The accompanying notes are an integral part of these unaudited
condensed financial statements.
IMMUNOME, INC.
Condensed Statements
of Operations
(In thousands,
except share and per share data)
(unaudited)
| |
Three Months Ended September 30, | | |
Nine Months Ended September 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
Collaboration revenue | |
$ | 3,565 | | |
$ | — | | |
$ | 10,192 | | |
$ | — | |
Operating expenses: | |
| | | |
| | | |
| | | |
| | |
Research and development | |
| 3,823 | | |
| 5,225 | | |
| 13,452 | | |
| 19,020 | |
General and administrative | |
| 4,375 | | |
| 3,309 | | |
| 11,617 | | |
| 10,094 | |
Total operating expenses | |
| 8,198 | | |
| 8,534 | | |
| 25,069 | | |
| 29,114 | |
Loss from operations | |
| (4,633 | ) | |
| (8,534 | ) | |
| (14,877 | ) | |
| (29,114 | ) |
Interest income | |
| 288 | | |
| 1 | | |
| 705 | | |
| 4 | |
Net loss | |
$ | (4,345 | ) | |
$ | (8,533 | ) | |
$ | (14,172 | ) | |
$ | (29,110 | ) |
Deemed dividend arising from warrant modification | |
| — | | |
| (622 | ) | |
| — | | |
| (622 | ) |
Net loss attributable to common stockholders | |
| (4,345 | ) | |
$ | (9,155 | ) | |
| (14,172 | ) | |
$ | (29,732 | ) |
Per share information: | |
| | | |
| | | |
| | | |
| | |
Net loss per share of common stock, basic and diluted | |
$ | (0.36 | ) | |
$ | (0.75 | ) | |
$ | (1.16 | ) | |
$ | (2.45 | ) |
Weighted-average common shares outstanding, basic and diluted | |
| 12,202,335 | | |
| 12,127,501 | | |
| 12,194,277 | | |
| 12,125,947 | |
The accompanying notes are an integral part of these unaudited
condensed financial statements.
IMMUNOME, INC.
Condensed Statements
of Cash Flows
(In thousands)
(unaudited)
| |
Nine Months ended September 30, | |
| |
2023 | | |
2022 | |
Cash flows from operating activities: | |
| | | |
| | |
Net loss | |
$ | (14,172 | ) | |
$ | (29,110 | ) |
Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | |
| | | |
| | |
Depreciation and amortization | |
| 306 | | |
| 327 | |
Amortization of right-of-use asset | |
| 165 | | |
| 44 | |
Write-off of deferred offering costs | |
| 332 | | |
| — | |
Share-based compensation | |
| 3,340 | | |
| 3,977 | |
Changes in operating assets and liabilities: | |
| | | |
| | |
Prepaid expenses and other assets | |
| 1,553 | | |
| 5,236 | |
Accounts payable | |
| 71 | | |
| 62 | |
Accrued expenses and other current liabilities | |
| (1,452 | ) | |
| (2,471 | ) |
Deferred revenue | |
| 19,808 | | |
| — | |
Other long-term liabilities | |
| (60 | ) | |
| (72 | ) |
Net cash provided by (used in) operating activities | |
| 9,891 | | |
| (22,007 | ) |
Cash flows from investing activities: | |
| | | |
| | |
Purchases of property and equipment | |
| (482 | ) | |
| (176 | ) |
Net cash used in investing activities | |
| (482 | ) | |
| (176 | ) |
Cash flows from financing activities: | |
| | | |
| | |
Payment of offering costs | |
| (125 | ) | |
| — | |
Proceeds from PIPE financing | |
| 61,000 | | |
| — | |
Proceeds from exercise of stock options | |
| — | | |
| 32 | |
Proceeds from issuance of common stock under ATM, net | |
| 34 | | |
| — | |
Net cash provided by financing activities | |
| 60,909 | | |
| 32 | |
Net increase (decrease) in cash and cash equivalents and restricted cash | |
| 70,318 | | |
| (22,151 | ) |
Cash and cash equivalents and restricted cash at beginning of period | |
| 20,423 | | |
| 49,329 | |
Cash and cash equivalents and restricted cash at end of period | |
$ | 90,741 | | |
$ | 27,178 | |
| |
| | | |
| | |
Supplemental disclosures of cash flow information: | |
| | | |
| | |
Operating lease right-of-use asset and lease liability recorded due to lease extension | |
$ | 226 | | |
$ | — | |
Issuance of common stock to certain board of directors in lieu of accrued compensation | |
$ | 221 | | |
$ | — | |
Deferred offering costs in accrued expenses and other current liabilities | |
$ | 5 | | |
$ | — | |
Property and equipment included in accounts payable | |
$ | 315 | | |
$ | — | |
The accompanying notes are an integral part of these unaudited
condensed financial statements.
Investor
Contact
Corleen Roche
Chief Financial Officer
investors@immunome.com
Media Contact
Andrew W. Mielach
LifeSci Communications
amielach@lifescicomms.com
v3.23.3
Cover
|
Nov. 09, 2023 |
Cover [Abstract] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Nov. 09, 2023
|
Entity File Number |
001-39580
|
Entity Registrant Name |
Immunome,
Inc.
|
Entity Central Index Key |
0001472012
|
Entity Tax Identification Number |
77-0694340
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
665
Stockton Drive, Suite 300
|
Entity Address, City or Town |
Exton
|
Entity Address, State or Province |
PA
|
Entity Address, Postal Zip Code |
19342
|
City Area Code |
610
|
Local Phone Number |
321-3700
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common
Stock, $0.0001 par value per share
|
Trading Symbol |
IMNM
|
Security Exchange Name |
NASDAQ
|
Entity Emerging Growth Company |
true
|
Elected Not To Use the Extended Transition Period |
false
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Immunome (NASDAQ:IMNM)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Immunome (NASDAQ:IMNM)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024